ABBV · AbbVie Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $2.65 | first quarter | — |
|
|
|||
| adjusted gross margin ratio non-GAAP | 83.6% | first quarter | — |
|
|
|||
| adjusted operating margin ratio non-GAAP | 40.8% | first quarter | — |
|
|
|||
| adjusted R&D expense as a percent of net revenues non-GAAP | 15.1% | first quarter | — |
|
|
|||
| adjusted SG&A expense as a percent of net revenues non-GAAP | 22.7% | first quarter | — |
|
|
|||
| adjusted tax rate non-GAAP | 15.4% | first quarter | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABBV
this stock
AbbVie Inc.
|
$458.24B | +13.3% | +8.6% | 127.8 | 1.3% |
|
LLY
ELI LILLY & Co
|
$1.13T | +10.5% | +44.7% | 42.5 | 1.1% |
|
JNJ
Johnson & Johnson
|
$634.77B | +25.9% | +6.0% | 30.6 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$323.72B | +26.3% | +1.4% | 36.9 | 1.2% |
|
NVS
Novartis AG
|
$296.72B | +16.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABBV | +1.0% | +9.4% | +16.6% | +2.1% | +13.4% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +2.7% | +8.7% | +10.2% | +3.3% | +5.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.